Samyang Biopharmaceuticals win patent trial of ‘Palseron’ against global pharmas
Samyang Biopharmaceuticals(CEO Tae-Woong Um) announced on the 3rd the company has won the 1st trial of patent infringement related to ‘Palseron Inj(generic name: palonosetron hydrochloride)’ against Helsinn Healthcare SA., a global Swiss pharmaceutical company.
Last 21 December, Seoul Central Di...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.